Release Date: May 07, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

LivaNova PLC (NASDAQ:LIVN) achieved 10% organic revenue growth in Q1 2025, marking the 8th time in the past 9 quarters with double-digit growth. The Osprey trial for obstructive sleep apnea showed a 65% responder rate at 12 months, validating the potential of their neurostimulation therapy. Cardiopulmonary segment revenue increased by 15% year-over-year, with heart-lung machine revenue growing approximately 30%. Regulatory approval for the Essence heart-lung machine in China, the second-largest market after the US, was received ahead of schedule. The company has a strong cash position, with a cash balance of $738 million, up from $429 million at the end of 2024, allowing for strategic investments and debt repayment.

Negative Points

LivaNova PLC (NASDAQ:LIVN) recorded a $360 million liability related to an Italian Supreme Court decision, impacting financial results. The US epilepsy business experienced procedure deferrals due to a voluntary field safety notification, impacting revenue by less than $2 million. Adjusted gross margin decreased to 70% from 71% in the prior year, driven by unfavorable product mix and inflationary headwinds. The company faces an uncertain tariff environment, with an estimated impact of less than $5 million on adjusted operating income for the year. Adjusted R&D expenses decreased, reflecting investment optimization, but this could impact future innovation and development.

Q & A Highlights

Warning! GuruFocus has detected 2 Warning Sign with LIVN.

Q: Can you help us understand where the Osprey trial data puts you in terms of market competitiveness and your plans for commercial development? A: Ahmed Tull, Chief Innovation Officer: The Osprey trial enrolled more severe patients and did not exclude those with complete concentric collapse (CCC), achieving a 65% responder rate at 12 months. We plan to optimize this technology further using personalized titration. The modular PMA submission to the FDA is complete, and we anticipate a relatively quick review. Commercially, we are confident in our ability to market this ourselves but are also exploring partnerships. Full strategy details will be shared at the investor day.

Q: Can you provide more detail on the outlook for the Heart-Lung Machine (HLM) business and the oxygenator side? A: Vladimir Makassara, CEO: We've gained market share in oxygenators and are expanding capacity by 10% this year, with a new manufacturing line expected next year. For HLM, Essence placements are expected to reach 60% this year, with regulatory approval in China, our second-largest market. We maintain a price premium, which is a significant growth driver.

Story Continues

Q: Could you elaborate on the sustainability of the improvements in the OUS neuromodulation business and the updated guidance for that segment? A: Stephanie Bolton, President of Global Epilepsy: Our improved commercial execution outside the US is reflected in our first-quarter results. We've strengthened our team and customer segmentation, leading to organic patient demand. We expect continued performance improvement, with significant opportunities in the underpenetrated EU region.

Q: How are tariffs impacting your financials, and what mitigation strategies are in place? A: Alex Schwartzberg, CFO: We estimate a less than $5 million impact on adjusted operating income due to tariffs. Our manufacturing footprint is well-positioned, with neuromodulation products made in the US and cardiopulmonary products in Europe. We have assessed our supply chain and consider the impact negligible, with potential pricing actions as a mitigation strategy.

Q: Can you explain the increase in the guidance for the cardiopulmonary segment, especially with recent approvals in China? A: Alex Schwartzberg, CFO: We expect double-digit growth in HLM, with China approvals slightly ahead of schedule. While Q1 saw 30% growth, capital equipment sales are not linear, and we anticipate strong growth throughout the year. Our updated guidance for cardiopulmonary is now 9-10%, up from 7-8%.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments